In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. A cardiac marker test is a biomarker test used to diagnose a cardiac disease event or predict the likelihood of cardiac disease through the measurement of Troponin, Brain Natriuretic Peptide, Creatine Kinase Myocardial Band and other target molecules. GlobalData uses proprietary data and analytics to provide a comprehensive report on the cardiac marker tests devices market, including market shares of different players within Norway. Buy the latest report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Norway Cardiac Marker Tests Market Share

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

In 2022, GlobalData’s Market Model methodology determined that the leading player in the cardiac marker tests market in Norway was F. Hoffmann-La Roche followed by Siemens, Abbott Laboratories, Danaher, bioMerieux and Quidelortho.

Cardiac marker tests are categorized into lab-based biomarker and point of care biomarker tests. Laboratory Tests: Any tests that require transporting of patient samples to a laboratory, including those with rapid turnaround times, are defined as laboratory or lab-based tests. For this Cardiac Marker tests model, lab-based tests include laboratory troponin tests, laboratory BNP tests, and CK-MB laboratory tests. Point Of Care Tests: Point of Care Testing (POC) is defined as medical diagnostic testing performed outside the clinical laboratory in close proximity to where the patient is receiving care. POC is typically performed by non-laboratory personnel and the results are used for clinical decision making. POC has a range of complexity and procedures that vary from manual methodologies to automated analyzers. POC devices are often ‘handheld’ or may be small portable analyzers. For this Cardiac Marker tests model, POC tests include POC troponin tests, POC BNP tests, and other POC tests.

Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the cardiac marker tests devices market within Norway was expected to be over $9m in 2022.

For the latest complete market share analysis of cardiac marker tests device market in Norway, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.